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OBJECTIVE — Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) have
different pathophysiological abnormalities, and their combination may inﬂuence the effective-
ness of the primary prevention tools. The hypothesis was tested in this analysis, which was done
in a pooled sample of two Indian Diabetes Prevention Programmes (IDPP-1 and IDPP-2).
RESEARCH DESIGN AND METHODS — Researchers analyzed and followed up on
thedetailsof845ofthe869IGTsubjectsinthetwostudiesfor3years.Incidenceofdiabetesand
reversal to normoglycemia (normal glucose tolerance [NGT]) were assessed in group 1 with
baselineisolatedIGT(iIGT)(n667)andingroup2withIGTIFG(n178).Theproportion
developing diabetes in the groups were analyzed in the control arm with standard advice
(IDPP-1)(n125),lifestylemodiﬁcation(LSM)(297fromboth),metformin(n125,IDPP-1),




in group 1, P  0.000) and a lower rate of reversal to NGT (18 vs. 32.1%, P  0.000). Cox
regression analysis showed that effectiveness of intervention was not different in the presence of
fasting and postglucose glycemia after adjusting for confounding variables.
CONCLUSIONS — The effectiveness of primary prevention strategies appears to be similar
insubjectswithiIGTorwithcombinedIGTIFG.However,thepossibilityremainsthatalarger
study might show that the effectiveness is lower in those with the combined abnormality.
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I
mpaired glucose tolerance (IGT) and
impaired fasting glucose (IFG) have a
high potential to convert to type 2 dia-
betes. While an elevated basal hepatic
glucose output and impaired early phase
insulin secretion are the major abnormal-
ities in IFG, IGT is characterized by more
severe muscle insulin resistance (IR) and
defects in late insulin secretion (1).
Among Asian Indians, higher degrees of
IR and -cell dysfunction are seen in IFG
than in IGT (2).
Analysis of six prospective studies
among subjects with IGT showed that the
incidence of diabetes varied widely from
23 to 62% within two to twenty-seven
years of follow-up (3). The incidence was
higher among populations with high
prevalence of diabetes than in white pop-
ulations. Incidence rates of diabetes in
subjects with IFG or IGT or with a com-
bined abnormality were varied in differ-
ent populations (4–8).
Primarypreventionstudieshavebeen
done among subjects with IGT in differ-
ent ethnic populations (9–14). Among
these, only the Diabetes Reduction As-
sessmentwithRamiprilandRosiglitazone
Medication (DREAM) trial (12) recruited
subjectswitheitherisolatedIFG(iIFG)or
isolated IGT (iIGT) or both. Rosiglitazone
wasfoundtobeapotentagentinprevent-
ing diabetes in this trial (12). The Diabe-
tes Prevention Programme (DPP) (9)
recruited subjects with a fasting glucose
in the range of 5.3–6.9 mmol/l (95–125
mg/dl) and 2-h postglucose of 7.8–11
mmol/l (140–199 mg/dl) and nearly one-
third of the participants had IFG by the
present criteria (15).
ResultsoftheIndianDiabetesPreven-
tion Programme-1 (IDPP-1) showed that
a moderate lifestyle modiﬁcation (LSM)
or a small dose of metformin (500 mg/
day) reduced the risk of diabetes in a rel-
atively nonobese but insulin resistant
Asian Indian population (13). In the
IDPP-2 study, we noted that pioglitazone
did not improve the efﬁcacy of LSM in
Asian Indians (14). In both studies, sub-
jects with persistent IGT and fasting glu-
cose levels below 6.9 mmol/l were
recruited. Therefore, some participants
also had IFG. In view of the higher degree
of biochemical abnormalities occurring
when fasting and postprandial dysglyce-
mia coexisted, it was considered impor-
tant to study whether the combined
abnormalities inﬂuenced the cumulative
incidence of diabetes in comparison with
subjects with iIGT. To increase the sam-
plesize,datafrombothIDPPstudieswere
pooled.Theparticipants’baselinecharac-
teristics were identical in the two studies.
RESEARCH DESIGN AND
METHODS— IDPP-1 and IDPP-2
were 3-year prospective, randomized
controlled studies among Asian Indian
subjects with persistent IGT (13,14).
IDPP-1 had four groups: 1) control with
standard advice, 2) LSM, 3) treated with
metformin (500 mg/day), and 4) a com-
bination of LSM and metformin (13).
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IGT subjects using LSM and placebo as
the control group and LSM and pioglita-
zone (30 mg/day) as the intervention
group (14).
Sample selection for this analysis is
shown in the ﬂow chart in Figure 1 (Fig.
1).Thetwo-stageselectionprocedurewas
used for recruiting reproducible IGT
only.NocaseofisolatedIFGwasselected,
and the presence of IFG was not an inclu-
sion criterion.
In both studies the primary outcome
was the development of diabetes detected
by a standard oral glucose tolerance test
(OGTT) (fasting plasma glucose 7.0
mmol/l and/or 2-h post glucose 11.1
mmol/l) (15). Reversal to normal glucose
tolerance (fasting plasma glucose 6.1
mmol/l and 2-h plasma glucose tolerance
7.8 mmol/l) was also considered as an
outcome. All subjects underwent annual
OGTT. A semiannual postprandial capil-
lary glucose test was done. Diabetes de-
tected in any person was conﬁrmed with
an OGTT.
In IDPP-1, in a median follow-up of
30 months, the relative risk reductions
with the interventions were similar
(28.5% with LSM, 26.4% with met-
formin, and 28.2% with LSM and met-
formin) when compared with the control
group (13). In IDPP-2, the cumulative in-
cidences of diabetes at 36 months were
similar in the intervention (29.8%) and
placebo groups (31.6%) (14).
BMI, waist circumference, and blood
pressure were measured at baseline and
during each review. Plasma glucose was
measured (glucose oxidase method) at
fasting, 30 min, and 2 h during the
OGTT,andcorrespondingplasmainsulin
was measured using the radioimmunoas-
say kit of DiaSorin (Saluggia, Italy). In-
dexes of insulin resistance (homeostasis
model assessment of insulin resistance
[HOMA-IR]) (16) and early insulin secre-
tion [(30-min fasting insulin [pmol/l]) 
30-min glucose (mmol/l) (index of insu-
lin secretion [ I/G])] were calculated
(17). Subjects from both studies having
all the above measurements were in-
cluded for this analysis. Among the total
of 869 followed up for 3 years in both
studies, data on plasma insulin was not
available for 24 subjects. Hence this anal-
ysis was done using the data of 845 sub-
jects. Group 1 was deﬁned as having iIGT
(2-h plasma glucose 7.8–11.0 mmol/l,
140–199 mg/dl) and group 2 as those
with combined IFG (fasting 6.1–6.9
mmol/l, 110–125 mg/dl) and IGT. Data
were available for 667 subjects in group 1
and 178 subjects in group 2 (Fig. 1).
Inthisstudy,thegroupwithstandard
care from IDPP-1 was deﬁned as the con-
trol group. The LSM group included LSM
from IDPP-1 and the placebo group from
IDPP-2. The effect of LSM  drugs (met-
formin and pioglitazone) was analyzed
since the numbers with IGT  IFG were
small in the individual drug group, and
the outcome measures were present in
numbers inadequate for statistical
comparisons.
Statistical analysis
Means and SD are shown for normally
distributed variables. Student t test was
used for intergroup comparison. Median
values were used for skewed variables,
and Mann-Whitney U test was used for
the comparisons. Intergroup proportions
were compared using the 
2 test. Kaplan-
Meier survival analysis was used to cal-
culate the probability of cumulative
incidence of diabetes in the groups. Log-
Figure 1—The selection of original cohorts for the two studies, randomization, and the ﬁnal outcome in the available subjects at the 3rd-year
follow-up are shown. The selection criteria for this analysis and the baseline distribution of subjects in group 1 (iIGT) and group 2 (IGT  IFG) are
also shown.
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ues. Cox proportional hazard model
(enter method) was used to study the ef-
fect of independent variables on the inci-
dence of diabetes. Initially, the crude
effect of all interventions versus the con-
trol group was assessed separately by Cox
regression analysis in group 1 and group
2. Three models were computed as fol-
lows. In the ﬁrst model, all interventions
versus the control group (reference) and
group 2 versus group 1 (reference) were
entered as independent variables. In the
second model, the interaction of the two
variables was also included. In the third
model, the variables in the second model
were included after adjusting for age
(years), sex, BMI (kg/m
2), and IR. Fasting
values of glucose and insulin were not in-
cluded as HOMA-IR was calculated using
theseparameters.Statisticalanalyseswere
done using SPSS version 10.0 (SPSS, Chi-
cago, IL). A P value of 0.001 was con-
sidered signiﬁcant.
RESULTS— Baselinecharacteristicsof
subjects in group 1 and group 2 are
shown in Table 1. There was an excess of
males in both the original studies; hence,
an overrepresentation of men is also seen
in this analysis. Subjects with combined
abnormalities (group 2) had higher
plasma glucose concentrations (P 
0.000),higherHOMA-IR,andlowerI/G
values than the subjects with iIGT (group
1) (P  0.000).
Comparativeanalysisoftheoutcomes
in the groups in 3 years is shown in Table
2 in relation to the interventions. In
LSM  drug group, the incidence of dia-
betes was signiﬁcantly lower in group 1
when compared with group 2 (P 
0.000). In group 1, LSM and LSM  met-
formin signiﬁcantly reduced the inci-
dence of diabetes and increased the
reversaltonormalglucosetoleranceinre-
lationtothecontrolgroup(P0.000).In
group 2, none of the intervention meth-
ods produced a signiﬁcant beneﬁt. The
crude effect of all interventions on the in-
cidence of diabetes appeared to be stron-
geramongthesubjectsingroup1(hazard
ratio 0.547 [95% CI 0.400–0.747], P 
0.000) than in group 2 (0.792, [0.470–
1.335], P  0.382) when compared with
the control group.
Table 3 shows the results of the Cox
regression models. The ﬁrst model
showedthattheincidenceofdiabeteswas
reduced by the interventions. The effec-
tiveness of intervention appeared to be
signiﬁcantly more in the iIGT group than
in the group with IFG  IGT. The second
model showed lack of interaction be-
tween the groups and intervention. The
results were similar even after adjusting
for age, sex, BMI, and IR. After adjusting
for the confounding variables, the effec-
tiveness of intervention did not differ be-
tween the two study groups.
CONCLUSIONS — In the Asian In-
dian subjects, the prevention strategies
signiﬁcantly decreased the cumulative in-
cidence of diabetes in comparison with
the control group both in the group with
iIGT and in the group with IFG  IGT as
shown by the Cox regression analysis.
Thecrudeeffectofallinterventionsonthe
incidence of diabetes appeared to be
Table 1—Comparison of characteristics of study subjects with iIGT (group 1) and IGT  IFG
(group 2)
Variables Group 1 Group 2
n (%) 667 (78.9) 178 (21.1)
Men:Women 559:108 140:38
Age (years)* 45.5  6.0 46.0  5.8
BMI (kg/m
2)* 25.7  3.2 26.4  3.8
Waist circumference (cm)* 89.6  8.2 91.3  8.4
Blood pressure (mmHg)*
Systolic 120.4  13.7 119.4  12.5
Diastolic 75.0  9.6 75.6  10.2
Plasma glucose (mmol/l)*
Fasting 5.2  0.6 6.4  0.2**
30 min 9.4  1.7 10.6  1.7**
120 min 8.4  1.0 9.1  1.3**
Plasma insulin (pmol/l)†
Fasting 108 114
30 min 480 420
120 min 618 612
HOMA-IR† 4.2 5.5**
 I/G† 39.4 28.0**
*Means  SD, †median values,**P  0.000 vs. group 1.
Table 2—Glycemic outcome up to 3 years in relation to interventions
Outcome iIGT (group 1) IGT  IFG (group 2)
Control
n 99 26
NGT 14 (14.1) 4 (15.4)
IGT 34 (34.3) 5 (19.2)
Diabetes 51 (51.5) 17 (65.4)
LSM
n 224 73
NGT 80 (35.7)* 15 (20.5)
IGT 78 (34.8) 25 (34.2)
Diabetes 66 (29.5)* 33 (45.2)
Drug (metformin)
n 106 19
NGT 29 (27.4)* 1 (5.3)
IGT 36 (33.9) 4 (21.0)
Diabetes 41 (38.7) 14 (73.7)
LSM  drug
n 238 60
NGT 91 (38.2)* 12 (20.0)
IGT 81 (34.0) 12 (20.0)
Diabetes 66 (27.7)* 36 (60.0)**
Data are n (%). Intragroup comparison: *P  0.000 vs. control; intergroup comparison: **P  0.000.
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those with IFG  IGT. However, a test of
the interaction of the intervention effect
by glycemic status was not statistically
signiﬁcant.
Among the primary prevention stud-
ies,theDPP(9)hadnearlyone-thirdofits
participantshavingIFGbythepresentdi-
agnostic criteria (15). In the placebo
group, cumulative incidence of diabetes
was more than threefold higher when the
participants had basal fasting plasma glu-
cose in the range of 6.1–6.9 mmol/l ver-
sus those who had lower values. In the
former group, the relative risk reductions
with interventions were also lower, more
so with metformin (9).
In the DREAM trial, the annual con-
version to diabetes in the placebo group
was almost double in the participants
with combined glycemic abnormalities
than those with isolated abnormalities
(12).However,theprimaryoutcomewith
rosiglitazone was much the same, irre-
spective of the glycemic abnormality
present at randomization.
We have not studied the effectiveness
of pioglitazone in isolation. In our study,
pioglitazone did not improve the effec-
tivenessofLSM(14).ItmightbethatLSM
had produced the maximum possible
beneﬁt on the glycemic status, and hence
nofurtherimprovementwasseenbyadd-
ing an insulin sensitizer (13,14).
The beneﬁcial outcomes caused by
the intervention strategies in the IDPP-1
occurred due to improved insulin action
and insulin sensitivity. Subjects with
higher baseline IR and/or low-cell func-
tion had poor outcomes (18). It had been
suggested that the differences in insulin
sensitivity and insulin secretion between
IGT and IFG and the greater severity of
the abnormalities when both coexist
might predict different rates of progres-
sion to diabetes, and different pharmaco-
logicalagentsmightbeneededtotreatthe
pathophysiology (19).
Prospective studies in different popu-
lations have demonstrated higher rates of
development of diabetes in subjects hav-
ing combined IFG and IGT than in sub-
jects having either of the glycemic
abnormalities(4–6).Thehighestpropor-
tion of diabetes development among sub-
jects with IFG and IGT (72.7%) was
reported in a Brazilian Japanese popula-
tion (7). Differences in follow-up periods
and racial/ethnic differences among the
study subjects account for the varied
results.
The strength of the analysis lies in the
prospective nature of our studies. By
combiningtheresultsoftwostudiesusing
different interventions, we could assess
the impact of LSM and insulin sensitizers
on the incidence of diabetes. However,
the small sample sizes in the control and
metformin groups posed some limita-
tions. Moreover, due to the small num-
bers of subjects with combined IGT and
IFG, the analysis could not be done sepa-
rately in LSM  metformin and LSM 




to analyze the impact of prevention strat-
egies in subjects with IGT. Subjects with
isolatedIFGwerenotselected,andwedid
not aim to conﬁrm the presence of IFG in
both steps of screening.
The original IDPP cohorts had a male
excess. Therefore, possible differences in
the compliance to LSM among men and
women could not be assessed.
Insummary,interventionsforthepri-
mary prevention of diabetes work effec-
tively in subjects having either iIGT or a
combinationofIGTIFG.Althoughthis
study cannot conﬁrm that the primary
prevention of diabetes is more effective in
people with iIGT than in those with
IFG  IGT, the possibility remains that
such an effect may become apparent in a
larger study or a meta-analysis.
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